Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
56
ACAD Quote, Financials, Valuation and Earnings
Last price:
$27.87
Seasonality move
:
14.5%
Day range:
$27.65 - $27.96
52-week range:
$13.40 - $28.35
Dividend yield:
0%
P/E ratio:
17.93x
P/S ratio:
4.48x
P/B ratio:
5.14x
Volume:
1M
Avg. volume:
1.5M
1-year change:
63.27%
Market cap:
$4.7B
Revenue:
$957.8M
EPS (TTM):
$1.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.96% | -83.59% | $29.79 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-- | -$0.16 | -- | -44.74% | $9.67 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
|
SLNO
Soleno Therapeutics, Inc.
|
$48.1M | $0.08 | -- | -- | $113.54 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$58.7M | -- | 11.45% | -- | $11.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.87 | $29.79 | $4.7B | 17.93x | $0.00 | 0% | 4.48x |
|
ADMA
ADMA Biologics, Inc.
|
$19.53 | $25.67 | $4.6B | 22.93x | $0.00 | 0% | 9.83x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.29 | $9.67 | $318M | -- | $0.00 | 0% | -- |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.25 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.29x |
|
SLNO
Soleno Therapeutics, Inc.
|
$48.84 | $113.54 | $2.6B | -- | $0.00 | 0% | 24.19x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$6.84 | $11.75 | $404.2M | -- | $0.00 | 0% | 1.89x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 1.936 | 4.95% | 2.64x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
SLNO
Soleno Therapeutics, Inc.
|
9.62% | -1.583 | 1.45% | 15.77x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
SLNO
Soleno Therapeutics, Inc.
|
$64.9M | $22.7M | -23.2% | -26.56% | 34.41% | $43.6M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
ACADIA Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ACAD or ADMA?
ADMA Biologics, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 27.14%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About ACAD or ADMA?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $29.79, signalling upside risk potential of 7.04%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 31.69%. Given that ADMA Biologics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe ADMA Biologics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 ADMAADMA Biologics, Inc.3 0 0 -
Is ACAD or ADMA More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.670, which suggesting that the stock is 32.982% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock ACAD or ADMA?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or ADMA?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than ADMA Biologics, Inc. quarterly revenues of $134.2M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than ADMA Biologics, Inc.'s net income of $36.4M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.93x while ADMA Biologics, Inc.'s PE ratio is 22.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.48x versus 9.83x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.48x 17.93x $278.6M $71.8M ADMAADMA Biologics, Inc.9.83x 22.93x $134.2M $36.4M
-
Which has Higher Returns ACAD or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of --. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About ACAD or ALDX?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $29.79, signalling upside risk potential of 7.04%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 91.42%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 ALDXAldeyra Therapeutics, Inc.4 0 0 -
Is ACAD or ALDX More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.670, which suggesting that the stock is 32.982% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.
-
Which is a Better Dividend Stock ACAD or ALDX?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or ALDX?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.93x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.48x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.48x 17.93x $278.6M $71.8M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns ACAD or FOLD?
Amicus Therapeutics, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 10.24%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About ACAD or FOLD?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $29.79, signalling upside risk potential of 7.04%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.02%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is ACAD or FOLD More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.670, which suggesting that the stock is 32.982% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock ACAD or FOLD?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or FOLD?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.93x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.48x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.48x 17.93x $278.6M $71.8M FOLDAmicus Therapeutics, Inc.7.29x -- $169.1M $17.3M
-
Which has Higher Returns ACAD or SLNO?
Soleno Therapeutics, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 39.4%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Soleno Therapeutics, Inc.'s return on equity of -26.56%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M -
What do Analysts Say About ACAD or SLNO?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $29.79, signalling upside risk potential of 7.04%. On the other hand Soleno Therapeutics, Inc. has an analysts' consensus of $113.54 which suggests that it could grow by 132.47%. Given that Soleno Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 SLNOSoleno Therapeutics, Inc.11 0 0 -
Is ACAD or SLNO More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.670, which suggesting that the stock is 32.982% less volatile than S&P 500. In comparison Soleno Therapeutics, Inc. has a beta of -3.150, suggesting its less volatile than the S&P 500 by 415.022%.
-
Which is a Better Dividend Stock ACAD or SLNO?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Soleno Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or SLNO?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Soleno Therapeutics, Inc. quarterly revenues of $66M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Soleno Therapeutics, Inc.'s net income of $26M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.93x while Soleno Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.48x versus 24.19x for Soleno Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.48x 17.93x $278.6M $71.8M SLNOSoleno Therapeutics, Inc.24.19x -- $66M $26M
-
Which has Higher Returns ACAD or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of -40.15%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About ACAD or VNDA?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $29.79, signalling upside risk potential of 7.04%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 71.78%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is ACAD or VNDA More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.670, which suggesting that the stock is 32.982% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.
-
Which is a Better Dividend Stock ACAD or VNDA?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or VNDA?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.93x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.48x versus 1.89x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.48x 17.93x $278.6M $71.8M VNDAVanda Pharmaceuticals, Inc.1.89x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
